Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.88 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -5.9 | |||||
3-Year EPS without NRI Growth Rate | -12.2 | |||||
3-Year FCF Growth Rate | -15.5 | |||||
3-Year Book Growth Rate | -22.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 64.5 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.17 | |||||
9-Day RSI | 39 | |||||
14-Day RSI | 43.92 | |||||
6-1 Month Momentum % | 2.03 | |||||
12-1 Month Momentum % | 36.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.55 | |||||
Quick Ratio | 8.55 | |||||
Cash Ratio | 7.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.3 | |||||
Shareholder Yield % | 0.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -98.21 | |||||
ROA % | -83.53 | |||||
ROIC % | -694.01 | |||||
3-Year ROIIC % | -322043.48 | |||||
ROC (Joel Greenblatt) % | -1573.15 | |||||
ROCE % | -97.76 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.56 | |||||
Price-to-Tangible-Book | 2.56 | |||||
EV-to-EBIT | -2.15 | |||||
EV-to-EBITDA | -2.16 | |||||
EV-to-Forward-Revenue | 17.6 | |||||
EV-to-FCF | -3.06 | |||||
Price-to-Net-Current-Asset-Value | 2.7 | |||||
Price-to-Net-Cash | 3.01 | |||||
Earnings Yield (Greenblatt) % | -46.51 | |||||
FCF Yield % | -23.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KALV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -3.58 | ||
Beta | -0.18 | ||
Volatility % | 66.62 | ||
14-Day RSI | 43.92 | ||
14-Day ATR ($) | 0.554596 | ||
20-Day SMA ($) | 11.769 | ||
12-1 Month Momentum % | 36.4 | ||
52-Week Range ($) | 7.21 - 16.88 | ||
Shares Outstanding (Mil) | 43.22 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
KalVista Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(KALV)'s stock price today?
When is next earnings date of KalVista Pharmaceuticals Inc(KALV)?
Does KalVista Pharmaceuticals Inc(KALV) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |